Tectonic, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs).
As many as a third of FDA-approved drugs target GPCRs in some fashion, with uses ranging from treating diabetes to pain. But biotech startups say there’s still room to develop more.